OBESITY AND THE metabolic syndrome have reached
|
|
- Marilyn Curtis
- 5 years ago
- Views:
Transcription
1 X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(6): Printed in U.S.A. Copyright 2004 by The Endocrine Society doi: /jc Adiponectin, Inflammation, and the Expression of the Metabolic Syndrome in Obese Individuals: The Impact of Rapid Weight Loss through Caloric Restriction ANTONIOS M. XYDAKIS, CHRISTOPHER C. CASE, PETER H. JONES, RON C. HOOGEVEEN, MINE-YINE LIU, E. O BRIAN SMITH, KATHLEEN W. NELSON, AND CHRISTIE M. BALLANTYNE Division of Endocrinology, Diabetes and Metabolism (A.M.X., C.C.C.), Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, and Section of Atherosclerosis, Department of Medicine (P.H.J., R.C.H., M.-Y.L., C.M.B.), and Section of Nutrition, Department of Pediatrics (E.O.S.), Baylor College of Medicine, Houston, Texas 77030; and Methodist Wellness Services (K.W.N.), The Methodist Hospital, Houston, Texas OBESITY AND THE metabolic syndrome have reached epidemic proportions in the United States, with deleterious public health consequences (1, 2). Since the publication of the National Cholesterol Education Program Adult Treatment Panel III (ATP III) diagnostic criteria for the metabolic syndrome (3), two independent studies indicated that more than one in five adults in the United States population qualifies for this diagnosis (4, 5). Insulin resistance is the hallmark of the metabolic syndrome, and it is strongly associated with excess adiposity (6, 7). Prevalence of the metabolic syndrome increases progressively from 5 and 6% of normal-weight [body mass index (BMI), 25 kg/m 2 ] men and women, respectively, to 22 and 28% of overweight (BMI, kg/m 2 ) men and women to 60 and 50% of obese (BMI, 30 kg/m 2 ) men and women (5). Furthermore, caloric restriction and weight reduction are beneficial in enhancing insulin action on peripheral tissues (8, 9) and preventing the development of type 2 diabetes (10). The relationship between insulin resistance and obesity is Abbreviations: ATP III, Adult Treatment Panel III; BMI, body mass index; CI, confidence interval; GGT, -glutamyltransferase; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, insulin resistance of the homeostasis model assessment; hs-crp, high-sensitivity C-reactive protein; MS, metabolic syndrome positive; MS, metabolic syndrome negative; NEFA, nonesterified fatty acid; OR, odds ratio; PPAR-, peroxisome proliferator-activated receptor- ; TG, triglyceride; VLCD, very low-calorie diet. JCEM is published monthly by The Endocrine Society ( endo-society.org), the foremost professional society serving the endocrine community. Severe obesity increases the prevalence of the metabolic syndrome, and moderate acute weight loss with a very low-calorie diet in obese subjects with the metabolic syndrome leads to significant metabolic benefits. Adiponectin has been implicated in both the pathogenesis of obesity-related insulin resistance and increased inflammation. We analyzed the relationship of the adipocyte-derived hormone adiponectin with indices of inflammation, adiposity, and insulin resistance in obese subjects with (MS, n 40) and without (MS, n 40) the metabolic syndrome and examined the acute effects of rapid weight loss. MS subjects had significantly lower adiponectin ( vs g/ml; P 0.003) and significantly higher TNF- ( vs pg/ml; P 0.004) levels compared with MS subjects matched for age and body mass index. Plasma adiponectin and TNF- levels were inversely related to the number of metabolic syndrome factors in a stepwise manner. After 4 6 wk of weight loss, there was marked improvement in glucose, insulin, leptin, and triglycerides, whereas adiponectin and TNF- concentrations did not change. Thus, increases in plasma levels of adiponectin or reductions in TNF- are not required for marked improvements in glucose/insulin and lipid metabolism with acute weight loss. (J Clin Endocrinol Metab 89: , 2004) complex, and accumulated evidence indicates that adipose tissue is a hormonally active system involved in insulin action as well as glucose and lipid metabolism (11). A variety of adipocyte-derived biologically active molecules termed adipocytokines have been identified, including leptin, resistin, TNF-, and IL-6, that may contribute to obesity-linked metabolic abnormalities (12 15). More recently, adiponectin, which is exclusively expressed in adipose tissue and is abundant in human plasma, has been found to be decreased in individuals with obesity, type 2 diabetes, and coronary heart disease (16 20). Although the physiological role of adiponectin remains unclear, it appears that it may possess insulinsensitizing and potentially antiinflammatory and antiatherogenic properties (21 26). Furthermore, different modalities of weight loss as well as peroxisome proliferator-activated receptor- (PPAR- ) agonist therapy have been shown to increase adiponectin levels longitudinally (17, 27, 28). Although the prevalence of the metabolic syndrome increases markedly with severe obesity, many individuals with severe obesity have no clinical manifestations of the metabolic syndrome. Although the diagnostic criteria for ATP III require that an individual have at least three of the five clinical criteria, risk for cardiovascular events increases with the number of clinical criteria present (29). We have previously shown that moderate acute weight loss of 5 7% in 4 6 wk with a very low-calorie diet (VLCD) in obese subjects with the metabolic syndrome is associated with dramatic improvement in all aspects of the metabolic syndrome, although the individuals remained markedly obese (30). In this study, we examined the association between adiponectin and 2697
2 2698 J Clin Endocrinol Metab, June 2004, 89(6): Xydakis et al. Adiponectin, TNF, and Metabolic Syndrome the number of metabolic abnormalities constituting the metabolic syndrome in obese individuals. In addition, we examined the impact of rapid weight loss on levels of adiponectin and other adipocytokines in conjunction with parameters of the metabolic syndrome and measures of insulin resistance in obese individuals with the metabolic syndrome. Subject selection Subjects and Methods Obese individuals (56 women and 24 men; age, yr; BMI, kg/m 2 ) enrolled in a medically supervised rapid weight loss program were recruited for this study during a 12-month period (September 2001 to September 2002). The study protocol was approved by the Baylor College of Medicine Institutional Review Board, and written informed consent was obtained from each individual. The subjects were classified as metabolic syndrome positive (MS ) if they met three or more of the National Cholesterol Education Program ATP III criteria: waist circumference greater than 40 in. (102 cm) for men or greater than 35 in. (88 cm) for women; triglycerides (TGs) of 150 mg/dl (1.69 mmol/ liter) or greater; high-density lipoprotein cholesterol (HDL-C) less than 40 mg/dl (1.03 mmol/liter) for men or less than 50 mg/dl (1.29 mmol/ liter) for women; blood pressure of 130/85 mm Hg or greater or treated hypertension; and fasting glucose of 110 mg/dl (6.1 mmol/liter) or greater (3). Sequentially enrolled MS subjects (n 40) were compared with 40 obese subjects matched for age and BMI who did not have the metabolic syndrome (MS ) (Table 1). Of the MS subjects, 26 had one criterion for the metabolic syndrome (waist), and 14 had two criteria (five with elevated blood pressure, four with low HDL-C, three with elevated TGs, and two with impaired fasting glucose). The study participants did not receive any medication to lose weight or any other medication known to affect glucose tolerance, insulin secretion, or insulin sensitivity during the active weight loss period. Weight loss protocol description The weight loss program was offered in a tertiary care medical center to individuals who were either self-referred or referred by healthcare professionals. Weight reduction was induced by a protein-sparing VLCD of approximately kcal daily, supervised by a team of physicians, registered dietitians, and behaviorists. It consisted of meal replacement products (Nutrimed-Plus; Robard Corp., Mount Laurel, NJ; each serving contained 200 kcal, 6goffat, 26 g of protein, and 10 g of carbohydrate) alone or in combination with lean beef, fish, or poultry. TABLE 1. Anthropometric and metabolic variables of the two study groups Variables Metabolic syndrome Positive (n 40) Negative (n 40) Age (yr) Gender (F/M) 23/17 33/ BMI (kg/m 2 ) Weight (lb) Waist (in.) SBP (mm Hg) DBP (mm Hg) Glucose (mg/dl) TG (mg/dl) HDL-C (mg/dl) Insulin (pmol/liter) HOMA-IR NEFA (meq/liter) Leptin (pmol/liter) Adiponectin ( g/ml) hs-crp (mg/liter) TNF- (pg/ml) Values are expressed as means SE. F, Female; M, male; DBP, diastolic blood pressure; SBP, systolic blood pressure. P Daily protein intake was calculated as 1.5 g per kilogram of predetermined goal weight, and daily fluid intake was at a minimum of 2 liters. Entry criteria for the program included age greater than 18 yr and a BMI of 30 kg/m 2 or greater. Exclusion criteria were known eating disorder, cancer, use of lithium or corticosteroids, type 1 diabetes, active inflammatory bowel disease, active gout, liver disease, cardiovascular event within the past 3 months, endocrine causes of obesity, and pregnancy. Diuretic medications were discontinued before entering the program. Anthropometric and biochemical measurements All subjects were evaluated with a series of anthropometric measurements and tests for hematology, biochemistry, and hormonal functions after an overnight fast. None of the subjects was on any calorierestricting diet at the baseline evaluation. Biochemical measurements were performed at baseline for all 80 individuals and prospectively for the 40 MS subjects after 4 6 wk of active weight loss. Measurements of insulin resistance were obtained using the homeostasis model assessment [HOMA-IR fasting glucose (mg/dl) fasting insulin ( U/ ml)/22.5], as described previously (31). All biochemical measurements were performed on frozen plasma samples obtained by centrifugation of freshly drawn blood (3000 g for 20 min at 4 C) and subsequent storage at 70 C. Blood lipid profiles, including total cholesterol, HDL-C, calculated low-density lipoprotein cholesterol, TGs, and nonesterified fatty acids (NEFAs), as well as plasma -glutamyltransferase (GGT), concentrations were determined by enzymatic assays using a Hitachi 911 auto-analyzer (Roche Diagnostics, Indianapolis, IN). Plasma levels of adiponectin were measured by RIA according to the manufacturer s protocol (Linco Research, Inc., St. Charles, MO). High-sensitivity C-reactive protein (hs-crp) was assessed by the Denka Seiken (Tokyo, Japan) assay, which has been validated against the Dade Behring method. Plasma levels of leptin and insulin were determined on a Luminex-100 multianalyte profiling system using commercially available immunoassay panels (Linco Research, Inc.). Circulating TNF- levels were measured by high-sensitivity ELISA (R&D Systems, Inc., Minneapolis, MN). Statistical analyses Unless stated otherwise, data are expressed as the means se. Statistical analysis was made using SPSS version 11.5 (SPSS Inc., Chicago, IL). Because variables were often not normally distributed, group comparison was performed by the Mann-Whitney nonparametric test, and the Kruskal-Wallis test was used for comparison of more than two independent groups. Correlations between different variables were performed by the Spearman rank correlation test. Comparison of variables before and after weight loss intervention in the metabolic syndrome group (MS ) was assessed by the Wilcoxon signed rank test. The independent contribution of each variable was assessed by simultaneously including other variables as covariates by general linear model univariate analysis. Interactions were assessed in the general linear model, and none were detected. The TNF- data were log transformed to satisfy the assumptions of the general linear model. Multiple logistic regression was used to assess adiponectin as an independent predictor of the metabolic syndrome, while adjusting for other variables. P 0.05 was considered to be statistically significant for all analyses. Results Association of adiponectin to diagnosis and number of metabolic syndrome components Plasma adiponectin level was significantly lower in MS subjects compared with age- and BMI-matched MS individuals ( vs g/ml; P 0.003) (Table 1; Fig. 1A). When the MS and MS groups were compared with respect to adiponectin and other variables, the difference remained significant after adjustment for age (P 0.001), gender (P 0.003), BMI (P 0.002), insulin (P 0.01), HOMA-IR (P 0.01), leptin (P 0.002), and all these together (P 0.01). Although plasma adiponectin concentra-
3 Xydakis et al. Adiponectin, TNF, and Metabolic Syndrome J Clin Endocrinol Metab, June 2004, 89(6): tion was higher in women compared with men in the overall group, consistent with observations by others, this difference did not reach statistical significance ( vs g/ml; P 0.1). There was a stepwise decrease in plasma adiponectin levels in parallel to the number of metabolic syndrome components present, and subjects with four or five components of the metabolic syndrome had the lowest adiponectin concentration, g/ml (Table 2; Fig. 1B). This stepwise decrement in adiponectin levels remained significant even after adjustment for insulin (P 0.01) and HOMA (P 0.01). Using multiple logistic regression, we calculated that the odds ratio (OR) of the metabolic syndrome as predicted by adiponectin was 0.83 [95% confidence interval (CI), ; P 0.004], indicating that there was a 17% decrease in the odds of having the metabolic syndrome for each 1- g/ml increment in adiponectin levels. The OR did not change appreciably after adjustment for weight and BMI (OR, 0.85; 95% CI, ; P 0.02). Furthermore, the ORs FIG. 1. The plasma adiponectin level was significantly lower in patients with the metabolic syndrome (MS ) compared with patients without the metabolic syndrome (MS ) (A) and decreased in parallel to the number of metabolic syndrome components present (B). were not substantially different when adjusted for waist (OR, 0.81; 95% CI, ; P 0.005), blood pressure (OR, 0.77; 95% CI, ; P 0.002), glucose (OR, 0.84; 95% CI, ; P 0.009), and TG (OR, 0.81; 95% CI, ; P 0.03) but became nonsignificant after adjusting for HDL-C (P 0.3). With respect to inflammatory markers, plasma TNF- levels were significantly higher in the MS group compared with the MS group ( vs pg/ml; P 0.004) (Fig. 2A). This difference remained significant after adjustment for age (P 0.02), BMI (P 0.04), insulin (P 0.05), and leptin (P 0.02) but not when adjusted for gender (P 0.1). Levels of hs-crp were not significantly different between the two study groups. There was a stepwise increase in plasma TNF- levels in parallel to the number of metabolic syndrome components present (Fig. 2B). Univariate correlations at baseline In univariate analysis of baseline variables in all subjects (MS and MS ), plasma adiponectin was inversely correlated with surrogate measures of total and visceral adiposity (weight and waist circumference) and was reciprocally associated with insulin, HOMA-IR, and all traits of the metabolic syndrome, except blood pressure (Table 3). Furthermore, plasma adiponectin was inversely correlated with hs-crp but not with TNF-, NEFA, or leptin. Plasma adiponectin had the strongest correlation to HDL-C levels of all variables examined (Fig. 3). As shown with adiponectin, plasma TNF- was positively correlated with measures of adiposity (weight and waist circumference) and inversely correlated with insulin and HOMA-IR. There were also significant associations between TNF-, TG, and HDL-C (Table 3). Effects of rapid weight loss on anthropometric and metabolic parameters in subjects with the metabolic syndrome At 4 6 wk of intervention (mean follow-up of 36 d), the subjects lost, on average, 7% of their initial weight ( lbs). Values at baseline and 4 6 wk after active weight reduction for all measured variables are displayed in Table 4. All components of the metabolic syndrome, except HDL-C, improved significantly. HDL-C decreased significantly, as seen in other studies with acute weight loss through caloric restriction (32, 33). Plasma levels of insulin, HOMA-IR, leptin, and hs-crp decreased significantly, and changes in HOMA-IR and hs-crp correlated significantly with weight loss. In contrast, adiponectin, NEFA, and TNF- levels did not change significantly after 4 6 wk of rapid weight loss. TABLE 2. Adiposity surrogate measures and biochemical parameters based on metabolic syndrome components Metabolic syndrome components BMI (kg/m 2 ) a Waist (in.) b Insulin (pmol/liter) b hs-crp (mg/liter) a Leptin (pmol/liter) a Adiponectin ( g/ml) b TNF- (pg/ml) b Obesity alone (n 26) Obesity 1(n 14) Obesity 2 (n 40) Values are means SE. a Nonsignificant by Kruskal-Wallis test. b P
4 2700 J Clin Endocrinol Metab, June 2004, 89(6): Xydakis et al. Adiponectin, TNF, and Metabolic Syndrome FIG. 3. In univariate analysis (Spearman rank correlation test) of baseline variables pertaining to the metabolic syndrome, the plasma adiponectin level was most strongly correlated to the HDL-C level. TABLE 4. Effect of rapid weight loss in anthropometric and metabolic variables of subjects with the metabolic syndrome FIG. 2. The plasma TNF- level was significantly higher in patients with the metabolic syndrome (MS ) compared with patients without the metabolic syndrome (MS ) (A) and increased in parallel to the number of metabolic syndrome components present (B). TABLE 3. Baseline correlations (Spearman) of several parameters with plasma adiponectin and TNF- in subjects with and without the metabolic syndrome (n 80) Variable Plasma adiponectin Discussion Plasma TNF- R P R P Weight Waist SBP DBP Glucose TG HDL-C Insulin HOMA-IR hs-crp TNF NA NA NEFA Leptin DBP, Diastolic blood pressure; SBP, systolic blood pressure. Adipose tissue has been postulated to play a prominent role in both insulin resistance and the clinical expression of the metabolic syndrome, most likely mediated by increased release and peripheral tissue action of NEFA and by dysregulated production of adipocyte-secreted proteins, including leptin, adiponectin, resistin, TNF-, and IL-6 (11, 14, 15, Variables Before After P BMI (kg/m 2 ) Weight (lb) SBP (mm Hg) DBP (mm Hg) Glucose (mg/dl) TG (mg/dl) HDL-C (mg/dl) LDL-C (mg/dl) NEFA (meq/ml) GGT (mg/dl) hs-crp (mg/liter) Insulin (pmol/liter) HOMA-IR Leptin (pmol/liter) Adiponectin ( g/ml) TNF- (pg/ml) Values are expressed as means SE. P values are by the Wilcoxon signed rank test. DBP, Diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure. 34). Of these proteins, adiponectin has recently been proposed as an important mediator of insulin action and glucose metabolism (13). Adiponectin has been reported to be decreased in obesity and type 2 diabetes and to be inversely correlated with insulin and TG levels and positively correlated with HDL-C levels (16, 17). The present study confirms and extends these associations by demonstrating that plasma adiponectin levels are significantly lower in obese individuals with the metabolic syndrome when compared with obese individuals, matched for age and BMI, who do not have the metabolic syndrome. Furthermore, stepwise decreases in adiponectin were observed with increasing numbers of metabolic syndrome components. The predictive ability of adiponectin to distinguish the MS from the MS obese subjects remained significant after adjusting for both weight and BMI, suggesting that adiponectin may contribute to the expression of the metabolic syndrome phenotype independent of total adiposity. When each component of the metabolic syndrome was introduced separately as a covariate, the predictive ability of adiponectin to distinguish the MS from the MS obese subjects did not change substantially after adjusting for each variable but became nonsig-
5 Xydakis et al. Adiponectin, TNF, and Metabolic Syndrome J Clin Endocrinol Metab, June 2004, 89(6): nificant after adjusting for HDL-C, suggesting an important role of adiponectin in modulating HDL metabolism. Surprisingly, no change in adiponectin levels was observed after 4 6 wk of weight loss. Despite the persistence of obesity, there was a marked improvement in some aspects of the metabolic syndrome, such as blood pressure, glucose, and TG, but no significant change in TNF- and only a modest (statistically but not clinically significant) drop in hs-crp. As reported previously with acute weight loss associated with ongoing caloric restriction, HDL-C decreased. There are several reports suggesting that adiponectin directly modulates glucose tolerance and peripheral tissue insulin sensitivity, possibly through AMP kinase activation (35, 36). Weight loss studies in humans have been used to support the hypothesis that increases in adiponectin may mediate improvement in insulin action and carbohydrate metabolism observed with weight loss (17, 28, 37). Three studies have demonstrated that a 10 22% weight reduction in obese individuals with VLCD or bariatric surgery was associated with a 36 51% increase in adiponectin levels (17, 28, 37). One study of 22 patients showed a substantial increase in adiponectin levels after 2 months of VLCD with an average weight loss of more than 10% (28), whereas the other studies with bariatric surgery observed improved adiponectin levels with even greater weight loss (17, 37). In contrast, in our study of acute VLCD-induced weight loss, which specifically assessed adipocytokines in an obese population with the metabolic syndrome, we observed marked improvements in glucose, insulin levels, and HOMA-IR within 4 6 wk that were not associated with any significant change in adiponectin levels. In general, expression of adiponectin in plasma correlates well with expression in adipose tissue. Therefore, it is unlikely that the improvements in glucose, insulin, and HOMA-IR, which are all reflective of improved whole-body insulin sensitivity, were related to changes in adiponectin. Our data are consistent with the data from a 6-month weight loss study that achieved a 6% reduction in BMI with diet and exercise and had no significant change in adiponectin levels but did have modest significant reductions in insulin (15%) and glucose (6%) (38). This 6-month study differs from our study in numerous aspects: TG was not reported, patients were not selected on the basis of the metabolic syndrome, average BMI was lower (32 vs. 37), and only postmenopausal women were included. The data from our study are consistent with a proposed model in which reductions in adiponectin levels reflect adipocyte dysregulation or malfunction rather than being causative of insulin resistance. Although unlikely, we cannot exclude the possibility that specific metabolic consequences induced by the VLCD resulted in the lack of change in adiponectin. In the same context, one potential limitation of our study is the lack of an isocaloric steady state at the follow-up evaluation, because subjects were in persistent caloric deficit at that time point. In agreement with our observations, Abbasi et al. (39) have recently shown that there is a significant overlap in adiponectin values between insulin-sensitive and insulin-resistant individuals (assessed by steady state plasma glucose concentration at the end of a 180-min infusion of octreotide, insulin, and glucose) and that a low adiponectin concentration is not uncommon in insulin-sensitive subjects. Furthermore, intervention modalities known to increase peripheral glucose disposal and insulin sensitivity, such as exercise or metformin therapy, do not alter adiponectin levels (40, 41). Thiazolidinediones or PPAR- agonists have been shown to increase adiponectin levels in vitro and in vivo, although the exact mechanism for this action has not been elucidated (27, 42, 43). It has been suggested that the up-regulation of PPAR- transcriptional activity and the resulting effect on adipocyte differentiation positively influences adiponectin secretion independent of the insulinsensitizing properties of these compounds (41). An emerging paradigm proposed to explain the link between excess adiposity and insulin resistance involves the metabolic diversion and ectopic storage of energy substrates (predominantly TG) from adipose to nonadipose tissues, particularly muscle and liver (44, 45). Our results are consistent with this hypothesis, because early mobilization of intracellular lipid from muscle (46) and liver (47) in response to rapid weight loss would be expected to enhance insulin action and decrease plasma levels of insulin, glucose, TG, and GGT acutely, by augmenting substrate transport and utilization (9, 48), despite the fact that our patients remained markedly obese. It is possible that a substantially greater and sustained weight reduction is necessary to correct altered adipocyte function, which could be determined by increased levels of adiponectin and reduced levels of TNF- and NEFA (49). Our study confirmed the association between adiponectin and dyslipidemia in nondiabetic obese subjects, demonstrating a reciprocal association with TG and a strong positive correlation with HDL-C. Although the precise mechanism for this association is unknown, it has been postulated that insulin resistance and/or hyperinsulinemia might offer an explanation in the case of insulin-resistant states, such as obesity, type 2 diabetes, and the metabolic syndrome. Interestingly, in our study the strong positive correlation between adiponectin and HDL-C remained significant even after adjusting for all components of the metabolic syndrome, insulin resistance, and adiposity measures both at baseline and after weight reduction. The adiponectin receptors AdipoR1 and AdipoR2 are associated with PPAR- activity and fatty acid oxidation (50), and thus the strong positive correlation between adiponectin and HDL-C levels may be secondary to modulation of HDL metabolism by adiponectin (51). Adiponectin may also play a role in regulating inflammatory responses. We confirmed the reciprocal association between adiponectin and hs-crp. Although we did not find a clear association of adiponectin and TNF-, which differs from in vitro data (52, 53), the relationship between TNF- and adiponectin in vivo may be complex because it has been suggested that TNF- may regulate adiponectin expression through autocrine and paracrine pathways (37). TNF-, in addition to adiponectin, has been postulated to play a causal role in the development of obesity-induced insulin resistance. To our knowledge, this is the first study demonstrating the stepwise increase in TNF- levels in parallel to the number of metabolic syndrome components present. In vitro studies have shown that adiponectin can decrease endothelialleukocyte adhesion through inhibition of endothelial nuclear factor- B signaling (18, 23). Mice deficient in adiponectin
6 2702 J Clin Endocrinol Metab, June 2004, 89(6): Xydakis et al. Adiponectin, TNF, and Metabolic Syndrome have increased neointimal proliferation after injury and increased atherosclerosis (24). In summary, we have shown that adiponectin is inversely associated with the expression of the metabolic syndrome and its individual traits in obese individuals, with a stepwise decrease in adiponectin levels with greater numbers of metabolic syndrome-defining criteria. Rapid weight loss through ongoing caloric restriction (7%, on average, over 4 6 wk) by a protein-sparing VLCD in obese individuals with the metabolic syndrome led to impressive reductions in insulin, glucose, TG, and blood pressure without the expected concomitant change in adiponectin or TNF- and only a modest reduction in hs-crp. These data are supportive of a proposed model that relates rapid weight loss to early mobilization of ectopic fat from liver and skeletal muscle, thereby reducing GGT, TG, glucose, insulin, and HOMA-IR, although subjects remained markedly obese after weight loss. We postulate that the lack of change in adiponectin and TNF- and the very modest decrease in hs-crp reflect persistent adipocyte dysregulation despite initiation of a rapid weight loss intervention and that a critical amount of total adiposity must be lost before the adipocyte resumes a more balanced function. The association of adiponectin with HDL and inflammation merits additional studies in humans to examine whether pharmacological manipulation of adiponectin levels would favorably influence these parameters. Acknowledgments Received October 20, Accepted February 24, Address all correspondence and requests for reprints to: Christie M. Ballantyne, M.D., Baylor College of Medicine, 6565 Fannin Street, MS A-601, Houston, Texas cmb@bcm.tmc.edu. This work was supported by National Institutes of Health General Clinical Research Center Grant 5M01RR00350 and Texas Applied Technology Program Grant The atherosclerosis laboratory was supported by donations from George and Cynthia Mitchell, Nijad Fares, and Jeffrey Hines. References 1. Flegal KM, Carroll MD, Ogden CL, Johnson CL 2002 Prevalence and trends in obesity among US adults, JAMA 288: Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT 2002 The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288: Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults 2001 Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285: Ford ES, Giles WH, Dietz WH 2002 Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287: Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB 2003 The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, Arch Intern Med 163: Kahn BB, Flier JS 2000 Obesity and insulin resistance. J Clin Invest 106: Maison P, Byrne CD, Hales CN, Day NE, Wareham NJ 2001 Do different dimensions of the metabolic syndrome change together over time? Evidence supporting obesity as the central feature. Diabetes Care 24: Goodpaster BH, Kelley DE, Wing RR, Meier A, Thaete FL 1999 Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes 48: Kelley DE, Goodpaster B, Wing RR, Simoneau JA 1999 Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. Am J Physiol Endocrinol Metab 277:E1130 E Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM 2002 Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: Trayhurn P, Beattie JH 2001 Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 60: Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Muller C, Carling D, Kahn BB 2002 Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415: Matsuzawa Y, Funahashi T, Nakamura T 1999 Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann NY Acad Sci 892: McTernan CL, McTernan PG, Harte AL, Levick PL, Barnett AH, Kumar S 2002 Resistin, central obesity, and type 2 diabetes. Lancet 359: Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G 2001 Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280:E745 E Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y 1999 Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257: Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y 2000 Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20: Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y 1999 Novel modulator for endothelial adhesion molecules: adipocytederived plasma protein adiponectin. Circulation 100: Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA 2001 Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86: Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, Arita Y, Okamoto Y, Shimomura I, Hiraoka H, Nakamura T, Funahashi T, Matsuzawa Y 2003 Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23: Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki K, Uchida S, Ito Y, Takakuwa K, Matsui J, Takata M, Eto K, Terauchi Y, Komeda K, Tsunoda M, Murakami K, Ohnishi Y, Naitoh T, Yamamura K, Ueyama Y, Froguel P, Kimura S, Nagai R, Kadowaki T 2003 Globular adiponectin protected ob/ob mice from diabetes and apoe-deficient mice from atherosclerosis. J Biol Chem 278: Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T 2001 The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7: Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y 2000 Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF- B signaling through a camp-dependent pathway. Circulation 102: Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, Kumada M, Ohashi K, Sakai N, Shimomura I, Kobayashi H, Terasaka N, Inaba T, Funahashi T, Matsuzawa Y 2002 Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106: Okamoto Y, Arita Y, Nishida M, Muraguchi M, Ouchi N, Takahashi M, Igura T, Inui Y, Kihara S, Nakamura T, Yamashita S, Miyagawa J, Funahashi T, Matsuzawa Y 2000 An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res 32: Matsuzawa Y, Funahashi T, Nakamura T 2002 Molecular mechanism of vascular disease in metabolic syndrome X. J Diabetes Complications 16: Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, Olefsky JM 2002 The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51: Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, Chen CL, Tai TY, Chuang LM 2001 Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 86: Ridker PM, Buring JE, Cook NR, Rifai N 2003 C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 107: Case CC, Jones PH, Nelson K, O Brian Smith E, Ballantyne CM 2002 Impact of weight loss on the metabolic syndrome. Diabetes Obes Metab 4: Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC 1985 Homeostasis model assessment: insulin resistance and -cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: Henry RR, Wiest-Kent TA, Scheaffer L, Kolterman OG, Olefsky J 1986
7 Xydakis et al. Adiponectin, TNF, and Metabolic Syndrome J Clin Endocrinol Metab, June 2004, 89(6): Metabolic consequences of very-low-calorie diet therapy in obese non-insulindependent diabetic and nondiabetic subjects. Diabetes 35: Dattilo AM, Kris-Etherton PM 1992 Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr 56: Hotamisligil GS, Spiegelman BM 1994 Tumor necrosis factor : a key component of the obesity-diabetes link. Diabetes 43: Tomas E, Tsao TS, Saha AK, Murrey HE, Zhang Cc C, Itani SI, Lodish HF, Ruderman NB 2002 Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-coa carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci USA 99: Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T 2002 Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMPactivated protein kinase. Nat Med 8: Bruun JM, Lihn AS, Verdich C, Pedersen SB, Toubro S, Astrup A, Richelsen B 2003 Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 285: E527 E Ryan AS, Nicklas BJ, Berman DM, Elahi D 2003 Adiponectin levels do not change with moderate dietary induced weight loss and exercise in obese postmenopausal women. Int J Obes Relat Metab Disord 27: Abbasi F, Chu J, McLaughlin T, Lamendola C, Reaven G, Hayden J, Reaven P 2003 Obesity versus insulin resistance in modulation of plasma adioponectin concentration. Diabetes 52(Suppl 1):A81 (Abstract) 40. Hulver MW, Zheng D, Tanner CJ, Houmard JA, Kraus WE, Slentz CA, Sinha MK, Pories WJ, MacDonald KG, Dohm GL 2002 Adiponectin is not altered with exercise training despite enhanced insulin action. Am J Physiol Endocrinol Metab 283:E861 E Phillips SA, Ciaraldi TP, Kong AP, Bandukwala R, Aroda V, Carter L, Baxi S, Mudaliar SR, Henry RR 2003 Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes 52: Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y 2001 PPAR ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50: Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y, Wang JP, Chen CL, Tai TY, Chuang LM 2002 Synthetic peroxisome proliferator-activated receptor- agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 25: Ravussin E, Smith SR 2002 Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and type 2 diabetes mellitus. Ann NY Acad Sci 967: Lewis GF, Carpentier A, Adeli K, Giacca A 2002 Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 23: Gray RE, Tanner CJ, Pories WJ, MacDonald KG, Houmard JA 2003 Effect of weight loss on muscle lipid content in morbidly obese subjects. Am J Physiol Endocrinol Metab 284:E726 E Tiikkainen M, Bergholm R, Vehkavaara S, Rissanen A, Hakkinen AM, Tamminen M, Teramo K, Yki-Jarvinen H 2003 Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content. Diabetes 52: Williams KV, Bertoldo A, Kinahan P, Cobelli C, Kelley DE 2003 Weight loss-induced plasticity of glucose transport and phosphorylation in the insulin resistance of obesity and type 2 diabetes. Diabetes 52: Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, Giugliano D 2003 Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 289: Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T 2003 Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423: Matsubara M, Maruoka S, Katayose S 2002 Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab 87: Kappes A, Loffler G 2000 Influences of ionomycin, dibutyryl-cycloamp and tumour necrosis factor- on intracellular amount and secretion of apm1 in differentiating primary human preadipocytes. Horm Metab Res 32: Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R 2002 Hormonal regulation of adiponectin gene expression in 3T3 L1 adipocytes. Biochem Biophys Res Commun 290: JCEM is published monthly by The Endocrine Society ( the foremost professional society serving the endocrine community.
An association between adipokines and insulin. Discrimination Between Obesity and Insulin Resistance in the Relationship With Adiponectin
Discrimination Between Obesity and Insulin Resistance in the Relationship With Adiponectin Fahim Abbasi, 1 James W. Chu, 1 Cindy Lamendola, 1 Tracey McLaughlin, 1 John Hayden, 2 Gerald M. Reaven, 1 Peter
More informationPossible Impairment of Transcardiac Utilization of Adiponectin in Patients With Type 2 Diabetes
Pathophysiology/Complications O R I G I N A L A R T I C L E Possible Impairment of Transcardiac Utilization of Adiponectin in Patients With Type 2 Diabetes MASATO FURUHASHI, MD 1,2 NOBUYUKI URA, MD 1 NORIHITO
More informationATHEROSCLEROTIC cardiovascular complications are the leading cause of. Diabetes Mellitus Has an Additional Effect on Coronary Artery Disease
Diabetes Mellitus Has an Additional Effect on Coronary Artery Disease To Decrease Plasma Adiponectin Levels Kuei-Chuan CHAN, 1 MD, Hsi-Hsien CHOU, 1 PhD, Der-Jinn WU, 1 PhD, Yi-Liang WU, 1 MD, and Chien-Ning
More informationAssociations among Lifestyle Status, Serum Adiponectin Level and Insulin Resistance
ORIGINAL ARTICLE Associations among Lifestyle Status, Serum Adiponectin Level and Insulin Resistance Hirokazu YOKOYAMA, Hiroshi HIROSE, Hideki OHGO* and Ikuo SAITO Abstract Objective The aim of this study
More informationAdiponectin is an adipose tissuespecific
Pathophysiology/Complications O R I G I N A L A R T I C L E Synthetic Peroxisome Proliferator Activated Receptor- Agonist, Rosiglitazone, Increases Plasma Levels of Adiponectin in Type 2 Diabetic Patients
More informationDecreased Serum Levels of Adiponectin Are a Risk Factor for the Progression to Type 2 Diabetes in the Japanese Population
Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E Decreased Serum Levels of Adiponectin Are a Risk Factor for the Progression to Type 2 Diabetes in the Japanese Population
More informationObesity, defined as excess fat accumulation, is the most
Association of Hypoadiponectinemia With Coronary Artery Disease in Men Masahiro Kumada, Shinji Kihara, Satoru Sumitsuji, Toshiharu Kawamoto, Satoru Matsumoto, Noriyuki Ouchi, Yukio Arita, Yoshihisa Okamoto,
More informationPlasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance
European Journal of Endocrinology (2003) 149 331 335 ISSN 0804-4643 CLINICAL STUDY Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance Josef
More informationChanges and clinical significance of serum vaspin levels in patients with type 2 diabetes
Changes and clinical significance of serum vaspin levels in patients with type 2 diabetes L. Yang*, S.J. Chen*, G.Y. Yuan, D. Wang and J.J. Chen Department of Endocrinology, Affiliated Hospital of Jiangsu
More informationAtherosclerotic diseases are the leading cause of death in
Adiponectin and Metabolic Syndrome Yuji Matsuzawa, Tohru Funahashi, Shinji Kihara, Iichiro Shimomura Abstract In this review article, the crucial roles of adipocytes in the development of so-called metabolic
More information3/20/2011. Body Mass Index (kg/[m 2 ]) Age at Issue (*BMI > 30, or ~ 30 lbs overweight for 5 4 woman) Mokdad A.H.
U.S. Adults: 1988 Nineteen states with 10-14% 14% Prevalence of Obesity (*BMI > 30, or ~ 30 lbs overweight for 5 4 woman) Metabolic John P. Cello, MD Professor of Medicine and Surgery, University of California,
More informationPrediction of Homeostasis Model Assessment of Insulin Resistance in Japanese Subjects
Tokai J Exp Clin Med., Vol. 37, No. 4, pp. 12-16, 212 Prediction of Homeostasis Model Assessment of Insulin Resistance in Japanese Subjects Masako NEGAMI, Eiko TAKAHASHI, Hiroki OTSUKA and Kengo MORIYAMA
More informationSerum Adiponectin Is Associated with Smoking Status in Healthy Korean Men
Endocrine Journal 2009, 56 (1), 73 78 Serum Adiponectin Is Associated with Smoking Status in Healthy Korean Men JAE WOONG SULL, HEE JIN KIM, JI EUN YUN, EUN JUNG PARK*, GRACE KIM** AND SUN HA JEE Institute
More informationAssociations of Adiponectin Levels With Incident Impaired Glucose Metabolism and Type 2 Diabetes in Older Men and Women
Cardiovascular and Metabolic Risk O R I G I N A L A R T I C L E Associations of Adiponectin Levels With Incident Impaired Glucose Metabolism and Type 2 Diabetes in Older Men and Women The Hoorn Study MARIEKE
More informationEffects of Antidiabetic Treatment with Metformin and Insulin on Serum and Adipose Tissue Adiponectin Levels in db/db Mice
Endocrine Journal 2005, 52 (4), 427 433 Effects of Antidiabetic Treatment with Metformin and Insulin on Serum and Adipose Tissue Adiponectin Levels in db/db Mice HIROKI FUJITA, HIROMI FUJISHIMA, JUN KOSHIMURA,
More informationAssociation of Insulin Resistance and Selected Adipokines in Cardiovascular Disease with and without Metabolic Syndrome
JMSCR Volume 2 Issue Pages 11-11 May www.jmscr.igmpublication.org Impact Factor-1.114 ISSN (e)-234-1x Association of Insulin Resistance and Selected Adipokines in Cardiovascular Disease with and without
More informationThe progressive impairment of carbohydrate
Pathophysiology/Complications O R I G I N A L A R T I C L E Plasma Adiponectin and Leptin Levels, Body Composition, and Glucose Utilization in Adult Women With Wide Ranges of Age and Obesity ALICE S. RYAN,
More informationDecreased plasma adiponectin concentrations in women with low-grade C-reactive protein elevation
European Journal of Endocrinology (2003) 148 657 662 ISSN 0804-4643 CLINICAL STUDY Decreased plasma adiponectin concentrations in women with low-grade C-reactive protein elevation Miyao Matsubara, Katsuhiko
More informationPlasma Levels of Adiponectin, a Novel Adipocyte-Derived Hormone, in Sleep Apnea
Plasma Levels of Adiponectin, a Novel Adipocyte-Derived Hormone, in Sleep Apnea Robert Wolk, Anna Svatikova, Christy A. Nelson, Apoor S. Gami, Kogilan Govender, Mikolaj Winnicki, and Virend K. Somers Abstract
More informationIn the past, adipose tissue was largely regarded as a
The Effect of Thiazolidinediones on Plasma Adiponectin Levels in Normal, Obese, and Type 2 Diabetic Subjects Joseph G. Yu, 1,2,3 Sandrine Javorschi, 4 Andrea L. Hevener, 1,2,3 Yolanta T. Kruszynska, 1,2,3
More informationORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults
ORIGINAL INVESTIGATION C-Reactive Protein Concentration and Incident Hypertension in Young Adults The CARDIA Study Susan G. Lakoski, MD, MS; David M. Herrington, MD, MHS; David M. Siscovick, MD, MPH; Stephen
More informationADIPONECTIN IS A new member of adipocytokines
0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(4):1833 1837 Printed in U.S.A. Copyright 2004 by The Endocrine Society doi: 10.1210/jc.2003-031260 Adiponectin in Anorexia Nervosa
More informationObesity is associated with dyslipidemia, hypertension,
Original Article Changes of Adiponectin Oligomer Composition by Moderate Weight Reduction Thomas Bobbert, 1,2 Helmut Rochlitz, 1,2 Uta Wegewitz, 1,2 Suzan Akpulat, 1,2 Knut Mai, 1,2 Martin O. Weickert,
More informationEmerging data suggest that bone mass regulates energy
Serum Osteocalcin Is Associated With Measures of Insulin Resistance, Adipokine Levels, and the Presence of Metabolic Syndrome Umer Saleem, Thomas H. Mosley, Jr, Iftikhar J. Kullo Objective Osteocalcin
More informationRelationship to visceral adiposity, insulin sensitivity, and -cell function
Metabolic Syndrome/Insulin Resistance Syndrome/Pre-Diabetes O R I G I N A L A R T I C L E Adiponectin in Youth Relationship to visceral adiposity, insulin sensitivity, and -cell function FIDA BACHA, MD
More informationFat Accumulation and Obesity-related Cardiovascular Risk Factors in Middle-aged Japanese Men and Women
ORIGINAL ARTICLE Fat Accumulation and Obesity-related Cardiovascular Risk Factors in Middle-aged Japanese Men and Women Miwa Ryo 1, Tohru Funahashi 1, Tadashi Nakamura 1, Shinji Kihara 1, Kazuaki Kotani
More informationOBESITY IS COMMONLY associated with insulin resistance
0021-972X/01/$03.00/0 Vol. 86, No. 5 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 2001 by The Endocrine Society Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close
More informationAdipocytes are a rich source of molecules that. Association Between Adiponectin and Mediators of Inflammation in Obese Women
Association Between Adiponectin and Mediators of Inflammation in Obese Women Stefan Engeli, 1 Mareike Feldpausch, 1 Kerstin Gorzelniak, 1 Frauke Hartwig, 1 Ute Heintze, 1 Jürgen Janke, 1 Matthias Möhlig,
More informationAdipose tissue serves not only as an energy
Plasma Adiponectin Concentration Is Associated With Skeletal Muscle Insulin Receptor Tyrosine Phosphorylation, and Low Plasma Concentration Precedes a Decrease in Whole-Body Insulin Sensitivity in Humans
More informationHUMAN ADIPONECTIN ENZYME IMMUNOASSAY KIT
Explore our innovative technologies for your research HUMAN ADIPONECTIN ENZYME IMMUNOASSAY KIT catalogue # A05185 96 wells TABLE OF CONTENTS Presentation 1 Precautions for use 1 Principle of the assay
More informationJournal of the American College of Cardiology Vol. 48, No. 2, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 48, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.03.043
More informationJMSCR Volume 03 Issue 04 Page April 2015
www.jmscr.igmpublication.org Impact Factor 3.79 ISSN (e)-2347-176x Study of Metabolic Syndrome and Thyroid Dysfunction Authors Dr. Nalini R Humaney, Dr. Saurabh Ashok Lande, Dr. Ramesh P Mundle N.K.P.Salve
More informationEffect of adiponectin on carotid arterial stiffness in type 2 diabetic patients treated with pioglitazone and metformin
Metabolism Clinical and Experimental 55 (2006) 996 1001 www.elsevier.com/locate/metabol Effect of adiponectin on carotid arterial stiffness in type 2 diabetic patients treated with pioglitazone and metformin
More informationSerum adiponectin levels in adults with Prader Willi syndrome are independent of anthropometrical parameters and do not change with GH treatment
European Journal of Endocrinology (2004) 151 457 461 ISSN 0804-4643 CLINICAL STUDY Serum adiponectin levels in adults with Prader Willi syndrome are independent of anthropometrical parameters and do not
More information902 Biomed Environ Sci, 2014; 27(11):
902 Biomed Environ Sci, 2014; 27(11): 902-906 Letter to the Editor Curcuminoids Target Decreasing Serum Adipocyte-fatty Acid Binding Protein Levels in Their Glucose-lowering Effect in Patients with Type
More informationCRP. Downloaded from ijdld.tums.ac.ir at 7:15 IRDT on Friday July 20th 2018 CRP HDL CRP FBS. t-student. correlation CRP
214-220 (2 ) 10 1389 -.. 1 2 1* 1 :. 21 40 :. HDL (TG) (FBS)... correlation t-student t :.(P=0/001) TG. (P=0/004) HDL : HDL FBS... : -1-2 ( )... : afagh_anjomshoaa@yahoo.com : 0241-7270815 : 0241-7270814
More informationAdipose tissue communicates with other peripheral
Expression of Adiponectin Receptor mrna in Human Skeletal Muscle Cells Is Related to In Vivo Parameters of Glucose and Lipid Metabolism Harald Staiger, Simone Kaltenbach, Katrin Staiger, Norbert Stefan,
More informationMetabolic and hormonal interactions between muscle and adipose tissue
Proceedings of the Nutrition Society (24), 63, 381 385 g The Authors 24 DOI:1.179/PNS24356 Metabolic and hormonal interactions between muscle and adipose tissue Eva Tomas 1, Meghan Kelly 1, Xiaoqin Xiang
More informationHIGH-FAT (HF) diet-induced insulin resistance associated
0163-769X/05/$20.00/0 Endocrine Reviews 26(3):439 451 Printed in U.S.A. Copyright 2005 by The Endocrine Society doi: 10.1210/er.2005-0005 Adiponectin and Adiponectin Receptors Takashi Kadowaki and Toshimasa
More informationInverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women
European Journal of Endocrinology (2002) 147 173 180 ISSN 0804-4643 CLINICAL STUDY Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women Miyao Matsubara,
More information2011, Editrice Kurtis
J. Endocrinol. Invest. : -, 2011 DOI: 10.2/902 The role of visfatin in the pathogenesis of gestational diabetes mellitus D.E. Gok 1, M. Yazici 1, G. Uckaya 1, S.E. Bolu 1, Y. Basaran 2, T. Ozgurtas, S.
More informationThe Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Update 2013 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine Denver Health
More informationDecreased plasma adiponectin concentrations in nondiabetic women with elevated homeostasis model assessment ratios
European Journal of Endocrinology (2003) 148 343 350 ISSN 0804-4643 CLINICAL STUDY Decreased plasma adiponectin concentrations in nondiabetic women with elevated homeostasis model assessment ratios Miyao
More informationTotal and high molecular weight adiponectin have similar utility for the identification of insulin resistance
CARDIO VASCULAR DIABETOLOGY ORIGINAL INVESTIGATION Open Access Original investigation Total and high molecular weight adiponectin have similar utility for the identification of insulin resistance Paloma
More informationLow serum adiponectin concentrations are associated with insulin sensitivity independent of obesity in Sudanese subjects with type 2 diabetes mellitus
Abdelgadir et al. Diabetology & Metabolic Syndrome 2013, 5:15 DIABETOLOGY & METABOLIC SYNDROME RESEARCH Open Access Low serum adiponectin concentrations are associated with insulin sensitivity independent
More informationFasting Insulin, Adiponectin, hs-crp Levels, and The Components of Metabolic Syndrome
ORIGINAL ARTICLE Fasting Insulin, Adiponectin, hs-crp Levels, and The Components of Metabolic Syndrome Fabiola MS Adam, Mario GB Nara, John MF Adam ABSTRACT Aim: in this study we report the relationship
More informationThe metabolic syndrome and adipocytokines
FEBS Letters 580 (2006) 2917 2921 Minireview The metabolic syndrome and adipocytokines Yuji Matsuzawa * Sumitomo Hospital, Professor Emeritus Osaka University, 5-3-20 Nakanoshima, Kita-Ku, Osaka 530-0005,
More informationFructose in Insulin Resistance- Focused on Diabetes 순천향대학교부천병원 내분비내과 정찬희
Fructose in Insulin Resistance- Focused on Diabetes 순천향대학교부천병원 내분비내과 정찬희 Introduction Unique characteristics of Fructose Metabolism Mechanism for Fructose-Induced Insulin Resistance Epidemiological Studies
More informationAdiponectin is independently associated with glycosylated haemoglobin
European Journal of Endocrinology (2004) 150 201 205 ISSN 0804-4643 CLINICAL STUDY Adiponectin is independently associated with glycosylated haemoglobin José Manuel Fernández-Real, Patricia Botas-Cervero
More informationHUMAN ADIPONECTIN HIGH SENSITIVITY ENZYME IMMUNOASSAY KIT
Explore our innovative technologies for your research HUMAN ADIPONECTIN HIGH SENSITIVITY ENZYME IMMUNOASSAY KIT catalogue # A05186 96 wells TABLE OF CONTENTS Presentation 1 Precautions for use 1 Principle
More informationALINA GAVRILA, JEAN L. CHAN, NIKOS YIANNAKOURIS, MEROPI KONTOGIANNI, LISA C. MILLER, CHRISTINE ORLOVA, AND CHRISTOS S. MANTZOROS
0021-972X/03/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 88(10):4823 4831 Printed in U.S.A. Copyright 2003 by The Endocrine Society doi: 10.1210/jc.2003-030214 Serum Adiponectin Levels
More informationFor Asian individuals the BMI numbers are 27.5 and 25 respectively These values are from the NICE guidelines of 2014
Ken Cathcart DO FACE We need to define several things to start the talk Obesity is defined medically as a BMI of greater than 30 or a BMI >27 with co-morbidities such as hypertension, type 2 DM, dyslipidemia,
More informationAtherosclerotic cardiovascular complications are the major
lasma Concentrations of a Novel, Adipose-Specific rotein, Adiponectin, in Type 2 atients Kikuko Hotta, Tohru Funahashi, Yukio Arita, Masahiko Takahashi, Morihiro Matsuda, Yoshihisa Okamoto, Hiromi Iwahashi,
More information300 Biomed Environ Sci, 2018; 31(4):
300 Biomed Environ Sci, 2018; 31(4): 300-305 Letter to the Editor Combined Influence of Insulin Resistance and Inflammatory Biomarkers on Type 2 Diabetes: A Population-based Prospective Cohort Study of
More informationAdiponectin is stimulated by adrenalectomy in ob/ob mice and is highly correlated with resistin mrna
Am J Physiol Endocrinol Metab 283: E1266 E1271, 2002. First published August 13, 2002; 10.1152/ajpendo.00227.2002. Adiponectin is stimulated by adrenalectomy in ob/ob mice and is highly correlated with
More informationHypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents
Hypertension with Comorbidities Treatment of Metabolic Risk Factors in Children and Adolescents Stella Stabouli Ass. Professor Pediatrics 1 st Department of Pediatrics Hippocratio Hospital Evaluation of
More informationElevated Serum Levels of Adropin in Patients with Type 2 Diabetes Mellitus and its Association with
Elevated Serum Levels of Adropin in Patients with Type 2 Diabetes Mellitus and its Association with Insulin Resistance Mehrnoosh Shanaki, Ph.D. Assistant Professor of Clinical Biochemistry Shahid Beheshti
More informationPlasma Adiponectin and Insulin Resistance in Korean Type 2 Diabetes Mellitus
Yonsei Medical Journal Vol. 46, No. 1, pp. 42-50, 2005 Plasma Adiponectin and Insulin Resistance in Korean Type 2 Diabetes Mellitus Mi-Jin Kim 1, Kwang-Ha Yoo 1, Hyung-Suk Park 1, Sang-Man Chung 1, Choon-Jo
More informationADIPONECTIN -THE MOLECULE OF THIS DECADE
2 : 28 ADIPONECTIN -THE MOLECULE OF THIS DECADE Adipocyte as we knew all these days was considered as a mere organ for deposition of fat however this view now is no longer tenable. We now know that adipocytes
More informationTable S2: Anthropometric, clinical, cardiovascular and appetite outcome changes over 8 weeks (baseline-week 8) by snack group
Table S1: Nutrient composition of cracker and almond snacks Cracker* Almond** Weight, g 77.5 g (5 sheets) 56.7 g (2 oz.) Energy, kcal 338 364 Carbohydrate, g (kcal) 62.5 12.6 Dietary fiber, g 2.5 8.1 Protein,
More informationType 2 diabetes mellitus is associated with lower serum adiponectin level in Bangladeshi population Abstract
16 Mediscope 2015;2(2):16-21 www.gmc.edu.bd ISSN: 2307-7689 Mediscope The Journal of GMC ORIGINAL ARTICLE Type 2 diabetes mellitus is associated with lower serum adiponectin level in Bangladeshi population
More informationTakashi Kadowaki Professor, Graduate School of Medicine, The University of Tokyo. for Molecular Basis of Type 2 Diabetes and Metabolic Syndrome
28 Japan Academy Prize to: Takashi Kadowaki Professor, Graduate School of Medicine, The University of Tokyo for Molecular Basis of Type 2 Diabetes and Metabolic Syndrome Outline of the work: Prof. Takashi
More informationThe promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease
The promise of the thiazolidinediones in the management of type 2 diabetes-associated cardiovascular disease Steve Smith, Group Director Scientific Affairs, Diabetes & Metabolism GlaxoSmithKline R & D
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationObesity, Metabolic Syndrome, and Diabetes: Making the Connections
Obesity, Metabolic Syndrome, and Diabetes: Making the Connections Alka M. Kanaya, M.D. Associate Professor of Medicine & Epi/Biostats University of California, San Francisco February 26, 21 Roadmap 1.
More informationMetabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Metabolic Syndrome Update 21 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes University of Colorado Denver Denver Health Medical Center The Metabolic
More informationImpact of Physical Activity on Metabolic Change in Type 2 Diabetes Mellitus Patients
2012 International Conference on Life Science and Engineering IPCBEE vol.45 (2012) (2012) IACSIT Press, Singapore DOI: 10.7763/IPCBEE. 2012. V45. 14 Impact of Physical Activity on Metabolic Change in Type
More informationAn association between plasma high-sensitivity
Differentiation Between Obesity and Insulin Resistance in the Association With C-Reactive Protein Tracey McLaughlin, MD; Fahim Abbasi, MD; Cindy Lamendola, RN, MSN; Lynn Liang, PhD; Gerald Reaven, MD;
More informationAssociation of serum adipose triglyceride lipase levels with obesity and diabetes
Association of serum adipose triglyceride lipase levels with obesity and diabetes L. Yang 1 *, S.J. Chen 1 *, G.Y. Yuan 1, L.B. Zhou 2, D. Wang 1, X.Z. Wang 1 and J.J. Chen 1 1 Department of Endocrinology,
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationEffect of Weight Loss and Lifestyle Changes on Vascular Inflammatory Markers in Obese Women
ORIGINAL CONTRIBUTION Effect of Weight Loss and Lifestyle s on Vascular Inflammatory Markers in Obese Women A Randomized Trial Katherine Esposito, MD Alessandro ontillo, MD Carmen Di alo Giovanni Giugliano,
More informationObesity in the pathogenesis of chronic disease
Portoroz October 16th 2013 Obesity in the pathogenesis of chronic disease Rocco Barazzoni University of Trieste Department of Medical, Surgical and Health Sciences Obesity Trends* Among U.S. Adults BRFSS,
More informationAdiponectin is an adipocyte-secreted
Pathophysiology/Complications O R I G I N A L A R T I C L E Total and High Molecular Weight Adiponectin in Relation to Metabolic Variables at Baseline and in Response to an Exercise Treatment Program Comparative
More informationDiabetes Day for Primary Care Clinicians Advances in Diabetes Care
Diabetes Day for Primary Care Clinicians Advances in Diabetes Care Elliot Sternthal, MD, FACP, FACE Chair New England AACE Diabetes Day Planning Committee Welcome and Introduction This presentation will:
More informationReview Establishment of a concept of visceral fat syndrome and discovery of adiponectin
No. 2] Proc. Jpn. Acad., Ser. B 86 (2010) 131 Review Establishment of a concept of visceral fat syndrome and discovery of adiponectin By Yuji MATSUZAWA 1,2, (Communicated by Hiroo IMURA, M.J.A.) Abstract:
More informationHealth benefits of mango supplementation as it relates to weight loss, body composition, and inflammation: a pilot study
Title of Study: Health benefits of mango supplementation as it relates to weight loss, body composition, and inflammation: a pilot study Principal Investigator: Dr. Edralin A. Lucas Nutritional Sciences
More informationIs socioeconomic position related to the prevalence of metabolic syndrome? Influence of
Is socioeconomic position related to the prevalence of metabolic syndrome? Influence of social class across the life-course in a population-based study of older men Sheena E Ramsay, MPH 1, Peter H Whincup,
More informationLipid profile Markers in Obese and Normal Weigh Individuals and their Relation with Obesity Determinants
ISSN No. (Print): 0975-1130 ISSN No. (Online): 2249-3239 Lipid profile Markers in Obese and Normal Weigh Individuals and their Relation with Obesity Determinants Assadi Fatemeh and Nooraei Farahnaz Department
More informationAssociation between arterial stiffness and cardiovascular risk factors in a pediatric population
+ Association between arterial stiffness and cardiovascular risk factors in a pediatric population Maria Perticone Department of Experimental and Clinical Medicine University Magna Graecia of Catanzaro
More informationRelationship between Insulin Resistance and Serum Levels of Adiponectin and Resistin with Childhood Obesity. Chao Chun Zou, Li Liang and Fang Hong
Research Papers Relationship between Insulin Resistance and Serum Levels of Adiponectin and Resistin with Childhood Obesity Chao Chun Zou, Li Liang and Fang Hong From the Children s Hospital of Zhejiang
More information8748 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 281 NUMBER 13 MARCH 31, 2006
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 281, NO. 13, pp. 8748 8755, March 31, 2006 2006 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in the U.S.A. Pioglitazone Ameliorates
More informationMetabolic Syndrome. Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah
Metabolic Syndrome Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah Objectives Be able to outline the pathophysiology of the metabolic syndrome Be able to list diagnostic criteria for
More informationHSN301 REVISION NOTES TOPIC 1 METABOLIC SYNDROME
HSN301 REVISION NOTES TOPIC 1 METABOLIC SYNDROME What does the term Metabolic Syndrome describe? Metabolic syndrome describes a cluster of cardio-metabolic conditions that increase one's risk of developing
More informationYiying Zhang, PhD Research Scientist. Research Summary:
Yiying Zhang, PhD Research Scientist Research Summary: Address: Naomi Berrie Diabetes Center at Columbia University Medical Center Russ Berrie Medical Science Pavilion 1150 St. Nicholas Avenue New York,
More informationARIC Manuscript Proposal # 979. PC Reviewed: 11/21/03 Status: Rejected Priority: SC Reviewed: Status: Priority:
ARIC Manuscript Proposal # 979 PC Reviewed: 11/21/03 Status: Rejected Priority: SC Reviewed: Status: Priority: 1.a. Full Title: Factors of the metabolic syndrome and incidence of coronary heart disease,
More informationOriginal Article Association of serum SPARC level with severity of coronary artery lesion in type 2 diabetic patients with coronary heart disease
Int J Clin Exp Med 2015;8(10):19290-19296 www.ijcem.com /ISSN:1940-5901/IJCEM0011299 Original Article Association of serum SPARC level with severity of coronary artery lesion in type 2 diabetic patients
More informationRelationship of adipokines with insulin sensitivity in African Americans.
Thomas Jefferson University Jefferson Digital Commons Department of Medicine Faculty Papers Department of Medicine 9-1-2011 Relationship of adipokines with insulin sensitivity in African Americans. Maria
More informationNutritional concerns of overweight / obese older persons. Gordon L Jensen, MD, PhD Dept Nutritional Sciences Penn State University
Nutritional concerns of overweight / obese older persons Gordon L Jensen, MD, PhD Dept Nutritional Sciences Penn State University Prevalence of obesity among older adults: NHANES 1999-2004 Sex Age (years)
More informationPlasma Retinol-Binding Protein-4 Concentrations Are Elevated in Human Subjects With Impaired Glucose Tolerance and Type 2 Diabetes
Pathophysiology/Complications O R I G I N A L A R T I C L E Plasma Retinol-Binding Protein-4 Concentrations Are Elevated in Human Subjects With Impaired Glucose Tolerance and Type 2 Diabetes YOUNG MIN
More informationThe investigation of serum lipids and prevalence of dyslipidemia in urban adult population of Warangal district, Andhra Pradesh, India
eissn: 09748369, www.biolmedonline.com The investigation of serum lipids and prevalence of dyslipidemia in urban adult population of Warangal district, Andhra Pradesh, India M Estari, AS Reddy, T Bikshapathi,
More informationContribution of Visceral Fat Accumulation to the Risk Factors for Atherosclerosis in Non-Obese Japanese
ORIGINAL ARTICLE Contribution of Visceral Fat Accumulation to the Risk Factors for Atherosclerosis in Non-Obese Japanese Takashi MIYAWAKI, Megumi ABE, Kensei YAHATA, Noboru KAJIYAMA, Hirokazu KATSUMA and
More informationMetabolic Syndrome: What s in a name?
Commentary Metabolic Syndrome: What s in a name? Deborah P. Wubben, MD, MPH; Alexandra K. Adams, MD, PhD Abstract The term metabolic syndrome has recently become en vogue. But is the definition realistic,
More informationContents. I. CV disease and insulin resistance: Challenges and opportunities. II. Insulin sensitizers: Surrogate and clinical outcomes studies
Contents I. CV disease and insulin resistance: Challenges and opportunities II. Insulin sensitizers: Surrogate and clinical outcomes studies IV. Identifying and treating patients with insulin resistance
More informationLow Plasma Adiponectin Levels Predict Progression of Coronary Artery Calcification
Low Plasma Adiponectin Levels Predict Progression of Coronary Artery Calcification David M. Maahs, MD; Lorraine G. Ogden, PhD; Gregory L. Kinney, MPH; Paul Wadwa, MD; Janet K. Snell-Bergeon, MPH; Dana
More informationDiabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome
Diabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome John E. Nestler, M.D. William Branch Porter Professor of Medicine Chair, Department of Internal Medicine Virginia Commonwealth University
More informationLEPTIN AS A NOVEL PREDICTOR OF DEPRESSION IN PATIENTS WITH THE METABOLIC SYNDROME
LEPTIN AS A NOVEL PREDICTOR OF DEPRESSION IN PATIENTS WITH THE METABOLIC SYNDROME Diana A. Chirinos, Ronald Goldberg, Elias Querales-Mago, Miriam Gutt, Judith R. McCalla, Marc Gellman and Neil Schneiderman
More informationMetabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine
Metabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine Setting the scene GB, 43 yo AA man followed for hypothyroidism returns on LT4 125 mcg/d and has a TSH=1.1
More informationEnergy Balance Equation
Energy Balance Equation Intake Expenditure Hunger Satiety Nutrient Absorption Metabolic Rate Thermogenesis Activity Eat to Live! Live to Eat! EAT TO LIVE Intake = Expenditure Weight Stable LIVE TO EAT
More information